Skip to main content
DIMERIX LIMITED logo

DIMERIX LIMITED — Investor Relations & Filings

Ticker · DXB ISIN · AU000000DXB7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,124 across all filing types
Latest filing 2008-09-28 Regulatory Filings
Country AU Australia
Listing ASX DXB

About DIMERIX LIMITED

https://dimerix.com/

Dimerix Limited focuses on the development of therapeutic treatments for inflammatory diseases, with a primary emphasis on kidney and respiratory conditions. The company utilizes its proprietary Receptor-Heteromer Investigation Technology (DMX-Technology) to identify and validate G protein-coupled receptor (GPCR) targets. Its lead candidate, DMX-200, is a chemokine receptor (CCR2) antagonist currently in Phase 3 clinical trials for the treatment of Focal Segmental Glomerulosclerosis (FSGS). The company is also advancing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD) and exploring applications for diabetic kidney disease. The core strategy involves targeting multiple signaling pathways simultaneously to address unmet medical needs in chronic inflammatory and fibrotic diseases.

Recent filings

Filing Released Lang Actions
Joint venture with Siyi 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX Company Announcement dated 29 September 2008 and 12 December 2007, describing a joint venture and cooperation agreement between Sun Biomedical Limited and Shanghai Siyi Biotechnology Co. Ltd. It discusses business arrangements, product approvals, and future plans but does not contain financial statements, earnings data, or detailed financial analysis. The document is a formal announcement of business developments and partnerships rather than a financial report or regulatory filing. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category for company disclosures that do not fit other specific categories.
2008-09-28 English
Appendix 3B 9 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is an ASX Company Announcement dated 18 September 2008 regarding the issue of new ordinary shares and options. It details the placement of shortfall under a rights issue prospectus, including the number and terms of securities issued, purpose of the funds raised, and application for quotation of additional securities. The document includes an Appendix 3B form, which is a standard ASX form for new issue announcements and applications for quotation of securities. There are no financial statements or detailed financial performance data present, nor is this a report or presentation. The content clearly relates to capital raising and changes in the company's capital structure through share and option issuance. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the capital raising event, not just an announcement of a report publication or a brief notice.
2008-09-17 English
Cleansing Statement 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a cleansing statement issued by Sun Biomedical Limited under section 708A(5) of the Corporations Act 2001. It details the issuance of shares and options without disclosure under Part 6D.2 of the Act and confirms compliance with relevant provisions. The content focuses on capital issuance and regulatory compliance related to fundraising activities. It is not a full financial report, earnings release, or management discussion. The document is short (1365 characters) and is an official announcement regarding capital structure changes. Therefore, it fits best under Capital/Financing Update (CAP).
2008-09-17 English
Shortfall Placement 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is an ASX Company Announcement dated 18 September 2008 regarding the issue of new ordinary shares and options. It details the amount raised, the number of shares and options placed, and references a Rights Issue Prospectus dated 26 June 2008. The content focuses on fundraising and capital raising activities, specifically the placement of shares and options under a rights issue. There are no financial statements or comprehensive financial data presented, nor is this a report or presentation. The document is clearly an update on capital raising activities, fitting the definition of a Capital/Financing Update (CAP). The document length is short and it is not announcing the publication of a report, so it is not an RPA. Therefore, the correct classification is CAP with high confidence.
2008-09-17 English
Appendix 3B 9 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is an ASX Company Announcement dated 16 September 2008 regarding the exercise of listed options and the issue of ordinary shares upon exercise. It includes an Appendix 3B, which is a standard form used for new issue announcements, application for quotation of additional securities, and agreements related to securities issuance on the Australian Securities Exchange (ASX). The content focuses on the issuance of shares, details of the securities, and compliance with ASX rules. There are no financial statements, management discussion, or detailed financial results. The document is a regulatory announcement about capital changes, specifically the issuance of shares due to option exercises. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2008-09-15 English
Response to an ASX Query - Director`s Interest Notice 4 pages ?Kb
Regulatory Filings Classification · 100% confidence The document is a letter from Sun Biomedical Limited responding to a query from ASX regarding the late lodgement of an Appendix 3Y, which is a Change of Director's Interest Notice. The content focuses on compliance with ASX listing rules 3.19A and 3.19B related to director disclosures and the company's arrangements to meet these obligations. There is no financial data, earnings information, or report content; rather, it is a regulatory compliance communication addressing a specific disclosure issue. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2008-09-07 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.